News | February 02, 2026
Dr Lal PathLabs reports Q3 revenue of Rs 660 crore, posts strong growth amid labour code impact
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
The Chennai facility will manufacture high-quality medical tubing for neurovascular and cardiovascular applications, including balloon catheters and other minimally invasive devices
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
Improvements were also seen in complete response rates, duration of response, and time to next treatment
Subscribe To Our Newsletter & Stay Updated
